A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors

Masanori Toyoda, Koichiro Watanabe, Taro Amagasaki, Kazuto Natsume, Hiromi Takeuchi, Cornelia Quadt, Kuniaki Shirao, Hironobu Minami, Masanori Toyoda, Koichiro Watanabe, Taro Amagasaki, Kazuto Natsume, Hiromi Takeuchi, Cornelia Quadt, Kuniaki Shirao, Hironobu Minami

Abstract

Purpose: BEZ235 is a dual kinase inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin, which are key components of the PI3K pathway. This was an open-label, multicenter, dose-escalation, phase I study of single-agent BEZ235 in Japanese oncology patients to determine the maximum tolerated dose (MTD) of BEZ235 based on dose-limiting toxicities (DLTs).

Methods: Dose escalation was guided by a standard 3 + 3 method and was based on DLTs observed in Cycle 1 and other safety, pharmacokinetic, and pharmacodynamic information. A total of 35 adult Japanese patients with advanced solid tumors received BEZ235 according to once daily (qd; n = 27) or twice daily (bid; n = 8) dosing schedules.

Results: Two DLTs, namely, allergic reaction and thrombocytopenia, were observed at 1200 and 1400 mg qd, respectively, while liver dysfunction was reported as a DLT at 400 mg bid. The most common adverse events suspected to be related to BEZ235 in both dosing schedules were diarrhea, nausea, decreased appetite, stomatitis, and thrombocytopenia.

Conclusions: Although the MTD was not established, the maximum clinically tolerable dose was determined to be 1200 mg because two out of six patients required dose reduction in Cycle 2. The recommended dose was determined to be 1000 mg qd, which was comparable with the results of the first-in-human BEZ235 study in Western patients with advanced solid tumors (NCT00620594). Additionally, the tolerability of BEZ235 400 mg bid in Japanese oncology patients was confirmed in this study. CLINICALTRIALS.

Gov identifier: NCT01195376.

Keywords: BEZ235; Inhibitor; PI3K; Phase I; mTOR.

Conflict of interest statement

Conflict of interest

Taro Amagasaki, Kazuto Natsume, Hiromi Takeuchi, and Cornelia Quadt are employees of Novartis. Hironobu Minami has received research funding from Novartis KK. The remaining authors declare no competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

    1. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA. 2005;102:802–807. doi: 10.1073/pnas.0408864102.
    1. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science. 2005;307:1098–1101. doi: 10.1126/science.1106148.
    1. Chow L, Baker S. PTEN function in normal and neoplastic growth. Cancer Lett. 2006;241:9817–9824. doi: 10.1016/j.canlet.2005.11.042.
    1. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology. 2005;25:1–7. doi: 10.1111/j.1440-1789.2004.00600.x.
    1. Zeng Z, Samudio IJ, Zhang W, et al. Simultaneous inhibition of PDK1/Akt and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006;66:3737–3746. doi: 10.1158/0008-5472.CAN-05-1278.
    1. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008;7:1851–1863. doi: 10.1158/1535-7163.MCT-08-0017.
    1. Burris H, Rodon J, Sharma S, et al. First-in-human phase I study of the oral dual PI3K and mTORC1/2 inhibitor BEZ235 in patients with advanced solid tumors. J Clin Oncol. 2010;28:3005. doi: 10.1200/jco.2010.28.15_suppl.3005.
    1. Rodon J, Infante J, Burris H, Tabernero JM (2010) A dose escalation study with a Special Drug Delivery System (SDS) of BEZ235, a novel dual PI3K/mTOR inhibitor, in patients with metastatic/advanced solid tumors. San Antonio Symposium. San Antonio, USA
    1. Rodon J, Pérez–Fidalgo A, Krop IE, et al. Phase I/Ib dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemother Pharmacol. 2018;82:285–298. doi: 10.1007/s00280-018-3610-z.
    1. Rodon A, Burris HA, Schellens JHM, et al. Phase I dose-escalation study of the oral dual mTOR/PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet formulation, in patients with advanced solid tumors. Eur J Cancer. 2012;48:112. doi: 10.1016/S0959-8049(12)71083-3.
    1. Peyton JD, Rodon Ahnert J, Burris H, et al. A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J Clin Oncol. 2011;29:3066. doi: 10.1200/jco.2011.29.15_suppl.3066.
    1. Bendell JC, Kurkjian C, Infante JR, et al. A phase I study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest New Drugs. 2015;33:463–471. doi: 10.1007/s10637-015-0218-6.
    1. Carlo MI, Molina AM, Lakhman Y. A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) andMammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. Oncologist. 2016;21:787–788. doi: 10.1634/theoncologist.2016-0145.
    1. Owonikoko TK, Ramalingam SS, Miller DL, et al. A translational, pharmacodynamic, and pharmacokinetic phase IB clinical study of everolimus in resectable non-small cell lung cancer. Clin Cancer Res. 2015;21:1859–1868. doi: 10.1158/1078-0432.CCR-14-1998.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj